Inclisiran is another first-in-class small interfering RNA (siRNA) against PCSK9 that has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia [13]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.